MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Sangamo Therapeutics Inc

Open

SectorGezondheidszorg

0.77 -7.23

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.78

Max

0.83

Belangrijke statistieken

By Trading Economics

Inkomsten

-34M

-23M

Verkoop

-42M

7.6M

EPS

-0.11

Winstmarge

-309.84

Werknemers

183

EBITDA

-34M

-24M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+517.28% upside

Dividenden

By Dow Jones

Volgende Winsten

8 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-45M

165M

Vorige openingsprijs

8

Vorige sluitingsprijs

0.77

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Sangamo Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 dec 2024, 11:35 UTC

Belangrijke Marktbewegers

Sangamo Shares Rally Premarket on License Deal With Astellas

Peer Vergelijking

Prijswijziging

Sangamo Therapeutics Inc Prognose

Koersdoel

By TipRanks

517.28% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5Ā USDĀ  517.28%

Hoogste 10Ā USD

Laagste 2Ā USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Sangamo Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

7 ratings

5

Buy

2

Hold

0

Sell

Technische score

By Trading Central

0.7379 / 0.8298Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Neutral Evidence

Lange Termijn

Weak Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.